Results from the first-in-human Phase I/II trial were presented by Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics. The study included 47 patients with a median age of 57 ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies ... zimberelimab and chemotherapy achieved “encouraging” response and progression-free ...

Preliminary immunogenicity results showed that the vaccine induced cancer antigen-specific T-cell responses in 10 of 13 evaluable patients (77%), which is "very encouraging," Tabatabai said.

3 "These new data could represent positive news in the future treatment of non-small cell lung cancer patients with activating HER2 mutations," said the trial’s principal investigator ...

Using the group of patients with very low or no ... and CAPOX as first-line treatment for advanced G/GEJ cancer are highly encouraging. The confirmed objective response rate and median progression ...

3 "These new data could represent positive news in the future treatment of non-small cell lung cancer patients with activating HER2 mutations," said the trial's principal investigator, Dr. John ...

plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed ...